Pharmacogenomics Technologies Market Share, Size, Trends, Industry Analysis Report, By Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others); By Therapeutic Area; By Region; And Segment Forecasts, 2023 - 2032

Pharmacogenomics Technologies Market Share, Size, Trends, Industry Analysis Report, By Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others); By Therapeutic Area; By Region; And Segment Forecasts, 2023 - 2032



The global pharmacogenomics technologies market size is expected to reach USD 14.10 billion by 2032, according to a new study by Polaris Market Research.

The report “Pharmacogenomics Technologies Market Share, Size, Trends, Industry Analysis Report, By Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others); By Therapeutic Area; By Region; And Segment Forecasts, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The field of diagnostics is undergoing a transformation as it adapts to the increasing availability of pharmacogenomic tests, often accompanying the introduction of new biological therapies. These tests have the dual benefit of not only providing cost-effective treatment options but also enhancing the drug development process.

The advantages associated with the adoption of these tests over traditional methods are substantial. First, they enable the prediction of disease risks, helping identify individuals who are more susceptible to certain conditions. Second, these tests aid in patient stratification, allowing healthcare providers to tailor treatments to the specific genetic characteristics of each patient. This personalized approach leads to more effective therapies and fewer adverse effects. Finally, pharmacogenomic tests are instrumental in monitoring therapeutic responses, ensuring that treatments are on track and adjustments can be made when necessary.

Pharmacogenomics testing products play a crucial role in assisting healthcare professionals in customizing and optimizing the therapeutic regimens for individual patients. The realms of pharmacogenomics and theranostics are opening new avenues for integrated medicine. The rapid advancements within this specialized category of molecular diagnostic tests are actively enhancing the assessment of real-time disease treatment, leading to improvements in patient care.

Nevertheless, there are challenges related to the timely integration of pharmacogenomic-based testing into drug development processes, which can hinder simultaneous approval. The effective design and execution of clinical trials aimed at identifying individual and population variations in response to a particular therapy have become essential factors for the success of theranostics.

Pharmacogenomics Technologies Market Report Highlights

The oncology segment is expected to witness the fastest growth during the forecast period, as there is growing onset of cancer, increasing need for personalized treatment, tumor profiling, rise in diagnosis rate, across the globe.

In 2022, PCR segment held the largest market share, as there are significant advancements in theranostics, advantages associated with its higher efficiency and high throughput screening coupled with adoption among end users.

In 2022, North America held the largest market share, owing to presence of key players, well developed industry big and small players, huge pool of researchers, and extensive network of industry academia.

The key market players include QIAGEN, GE HealthCare, Agilent Technologies, Roche, Foundation Medicine, Thermo Fisher Scientific., Leica Biosystems, and Pfizer.

Polaris Market Research has segmented the pharmacogenomics technologies market report based on technology, therapeutic area, and region:

Pharmacogenomics Technologies, Technology Outlook (Revenue - USD Billion, 2019 - 2032)

PCR

In-situ Hybridization

Immunohistochemistry

Sequencing

Others

Pharmacogenomics Technologies, Therapeutic Area Outlook (Revenue - USD Billion, 2019 - 2032)

Oncology

Lung Cancer

Breast Cancer

Colorectal Cancer

Cervical Cancer

Others

Neurological Disorders

Cardiovascular Disease

Immunological Disorders

Infectious Diseases

Others

Pharmacogenomics Technologies, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa


1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. Global Pharmacogenomics Technologies Market Insights
4.1. Pharmacogenomics Technologies Market – Industry Snapshot
4.2. Pharmacogenomics Technologies Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Increasing Awareness and Adoption of Personalized Healthcare
4.2.1.2. Advancements in Technology
4.2.2. Restraints and Challenges
4.2.2.1. Costs and Reimbursement
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTLE Analysis
4.5. Pharmacogenomics Technologies Industry trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis
5. Global Pharmacogenomics Technologies Market, by Technology
5.1. Key Findings
5.2. Introduction
5.2.1. Global Pharmacogenomics Technologies, by Technology, 2019-2032 (USD Billion)
5.3. PCR
5.3.1. Global Pharmacogenomics Technologies Market, by PCR, by Region, 2019-2032 (USD Billion)
5.4. In-situ Hybridization
5.4.1. Global Pharmacogenomics Technologies Market, by In-situ Hybridization, by Region, 2019-2032 (USD Billion)
5.5. Immunohistochemistry
5.5.1. Global Pharmacogenomics Technologies Market, by Immunohistochemistry, by Region, 2019-2032 (USD Billion)
5.6. Sequencing
5.6.1. Global Pharmacogenomics Technologies Market, by Sequencing, by Region, 2019-2032 (USD Billion)
5.7. Others
5.7.1. Global Pharmacogenomics Technologies Market, by Others, by Region, 2019-2032 (USD Billion)
6. Global Pharmacogenomics Technologies Market, by Therapeutic Area
6.1. Key Findings
6.2. Introduction
6.2.1. Global Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
6.3. Oncology
6.3.1. Global Pharmacogenomics Technologies Market, by Oncology, by Region, 2019-2032 (USD Billion)
6.3.2. Lung Cancer
6.3.2.1. Global Pharmacogenomics Technologies Market, by Lung Cancer, by Region, 2019-2032 (USD Billion)
6.3.3. Breast Cancer
6.3.3.1. Global Pharmacogenomics Technologies Market, by Breast Cancer, by Region, 2019-2032 (USD Billion)
6.3.4. Colorectal Cancer
6.3.4.1. Global Pharmacogenomics Technologies Market, by Colorectal Cancer, by Region, 2019-2032 (USD Billion)
6.3.5. Cervical Cancer
6.3.5.1. Global Pharmacogenomics Technologies Market, by Cervical Cancer, by Region, 2019-2032 (USD Billion)
6.3.6. Others
6.3.6.1. Global Pharmacogenomics Technologies Market, by Others, by Region, 2019-2032 (USD Billion)
6.4. Neurological Disorders
6.4.1. Global Pharmacogenomics Technologies Market, by Neurological Disorders, by Region, 2019-2032 (USD Billion)
6.5. Cardiovascular Disease
6.5.1. Global Pharmacogenomics Technologies Market, by Cardiovascular Disease, by Region, 2019-2032 (USD Billion)
6.6. Immunological Disorders
6.6.1. Global Pharmacogenomics Technologies Market, by Immunological Disorders, by Region, 2019-2032 (USD Billion)
6.7. Infectious Diseases
6.7.1. Global Pharmacogenomics Technologies Market, by Infectious Diseases, by Region, 2019-2032 (USD Billion)
6.8. Others
6.8.1. Global Pharmacogenomics Technologies Market, by Others, by Region, 2019-2032 (USD Billion)
7. Global Pharmacogenomics Technologies Market, by Geography
7.1. Key findings
7.2. Introduction
7.2.1. Pharmacogenomics Technologies Market Assessment, By Geography, 2019-2032 (USD Billion)
7.3. Pharmacogenomics Technologies Market – North America
7.3.1. North America: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.3.2. North America: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.3.3. Pharmacogenomics Technologies Market – U.S.
7.3.3.1. U.S.: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.3.3.2. U.S.: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.3.4. Pharmacogenomics Technologies Market – Canada
7.3.4.1. Canada: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.3.4.2. Canada: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.4. Pharmacogenomics Technologies Market – Europe
7.4.1. Europe: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.4.2. Europe: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.4.3. Pharmacogenomics Technologies Market – UK
7.4.3.1. UK: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.4.3.2. UK: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.4.4. Pharmacogenomics Technologies Market – France
7.4.4.1. France: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.4.4.2. France: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.4.5. Pharmacogenomics Technologies Market – Germany
7.4.5.1. Germany: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.4.5.2. Germany: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.4.6. Pharmacogenomics Technologies Market – Italy
7.4.6.1. Italy: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.4.6.2. Italy: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.4.7. Pharmacogenomics Technologies Market – Spain
7.4.7.1. Spain: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.4.7.2. Spain: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.4.8. Pharmacogenomics Technologies Market – Netherlands
7.4.8.1. Netherlands: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.4.8.2. Netherlands: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.4.9. Pharmacogenomics Technologies Market – Russia
7.4.9.1. Russia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.4.9.2. Russia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.5. Pharmacogenomics Technologies Market – Asia Pacific
7.5.1. Asia Pacific: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.5.2. Asia Pacific: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.5.3. Pharmacogenomics Technologies Market – China
7.5.3.1. China: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.5.3.2. China: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.5.4. Pharmacogenomics Technologies Market – India
7.5.4.1. India: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.5.4.2. India: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.5.5. Pharmacogenomics Technologies Market – Malaysia
7.5.5.1. Malaysia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.5.5.2. Malaysia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.5.6. Pharmacogenomics Technologies Market – Japan
7.5.6.1. Japan: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.5.6.2. Japan: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.5.7. Pharmacogenomics Technologies Market – Indonesia
7.5.7.1. Indonesia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.5.7.2. Indonesia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.5.8. Pharmacogenomics Technologies Market – South Korea
7.5.8.1. South Korea: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.5.8.2. South Korea: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.6. Pharmacogenomics Technologies Market – Middle East & Africa
7.6.1. Middle East & Africa: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.6.2. Middle East & Africa: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.6.3. Pharmacogenomics Technologies Market – Saudi Arabia
7.6.3.1. Saudi Arabia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.6.3.2. Saudi Arabia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.6.4. Pharmacogenomics Technologies Market – UAE
7.6.4.1. UAE: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.6.4.2. UAE: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.6.5. Pharmacogenomics Technologies Market – Israel
7.6.5.1. Israel: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.6.5.2. Israel: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.6.6. Pharmacogenomics Technologies Market – South Africa
7.6.6.1. South Africa: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.6.6.2. South Africa: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.7. Pharmacogenomics Technologies Market – Latin America
7.7.1. Latin America: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.7.2. Latin America: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.7.3. Pharmacogenomics Technologies Market – Mexico
7.7.3.1. Mexico: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.7.3.2. Mexico: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.7.4. Pharmacogenomics Technologies Market – Brazil
7.7.4.1. Brazil: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.7.4.2. Brazil: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
7.7.5. Pharmacogenomics Technologies Market – Argentina
7.7.5.1. Argentina: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
7.7.5.2. Argentina: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
8. Competitive Landscape
8.1. Expansion and Acquisition Analysis
8.1.1. Expansion
8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
9.1. Agilent Technologies, Inc.
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Recent Development
9.2. F. Hoffmann-La Roche Ltd
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Product Benchmarking
9.2.4. Recent Development
9.3. Foundation Medicine, Inc.
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Product Benchmarking
9.3.4. Recent Development
9.4. GE HealthCare
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Product Benchmarking
9.4.4. Recent Development
9.5. Illumina, Inc
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Product Benchmarking
9.5.4. Recent Development
9.6. Leica Biosystems Nussloch GmBH
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Product Benchmarking
9.6.4. Recent Development
9.7. MDPI
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Product Benchmarking
9.7.4. Recent Development
9.8. Pfizer Inc.
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Product Benchmarking
9.8.4. Recent Development
9.9. QIAGEN
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. Product Benchmarking
9.9.4. Recent Development
9.10. Thermo Fisher Scientific Inc
9.10.1. Company Overview
9.10.2. Financial Performance
9.10.3. Product Benchmarking
9.10.4. Recent Development

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings